Modelling the Societal Cost of Alzheimer's Disease (AD) in Australia and the Economic Impact of a Hypothetical Disease-Modifying Therapy as an Early Intervention to Prevent or Delay the Progression of Dementia

To undertake a budget impact analysis of Aducanumab - a disease-modifying therapy to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) that potentially prevents or delays the progression to dementia – on the societal costs of AD in Australia using a Markov decision-analytic model.